...show a resurgence in recalls related to application integrity issues. Potency problems continue to be the source of a high percentage of recalls. Overall, the number and types of drug product recalls reported in 1997 are in line with the 1996 tally. Labeling/packaging recalls are an exception, more than doubling from the prior year. Comments on a proposed cGMP rule modifying the cut labeling provisions are under review at FDA. Recalls of injectables also spike in 1997. FDA considers four drug recalls involving various dosage forms and one therapeutic biological recall dangerous enough to warrant a Class I rating. [A nine-page tabulation of recalls listed in FDA "Enforcement Reports" during 1997 is included.]
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.
The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.
The European Medicines Agency recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy as the US reported another death in an Elevidys patient.
